Close Menu

A*Star

The Singapore-based immune profiling firm aims to open a US facility by the end of the year and begin running projects out of it in the first quarter of 2021.

The Singapore-based company will use the funds to expand its presence in the US and develop its platform, which uses mass cytometry to profile T-cell response.

Avatamed will use the funds to expand into the Asia-Pacific market and set up a lab in Singapore to provide precision cancer drug screening services.

The alliance, led by Singapore-based startup Proteona, also includes several organizations from that city state as well as German research institutes.

The effort is focused on building an atlas of immune cell types found across a range of Asian population groups as part of the Human Cell Atlas project.

A*STAR and Tan Tock Seng Hospital developed the test, which is the first diagnostic to be deployed in the country's hospitals since the outbreak began in December.

Researchers in Singapore found fewer genetic alterations in tumors from East Asians than Europeans and identified a gene expression subtype specific to East Asians.

For the first phase of the SG10K project, researchers sequenced thousands of Chinese, Malay, or Indian individuals from Singapore, uncovering new variants and population insights.

The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.

The company will work with the Genome Institute of Singapore to create a test for breast cancer recurrence prediction using its circulating tumor cell platform.

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.